Journal Scan

Ganaxolone reduces frequency of CDKL5 deficiency disorder-associated seizures

Patients with CDKL5 deficiency disorder (CDD) had less frequent CDD-associated seizures when treated with an investigational neuroactive steroid, Ganaxolone, compared with placebo, according to the results of a phase 3 trial. In the double-blind phase of this randomized, placebo-controlled, 101 patients between the ages of 2-21 years with a pathogenic...